BioNexus Gene Lab Corp. (BGLC) Return on equity 2018–2025
BioNexus Gene Lab Corp. (BGLC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-34.6%FY2025 · since FY2018: 1.7% → -34.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -34.6% | -15.4 pp |
| FY2024 | -19.2% | +8.0 pp |
| FY2023 | -27.2% | -21.9 pp |
| FY2022 | -5.3% | -15.8 pp |
| FY2021 | 10.5% | -6.0 pp |
| FY2020 | 16.4% | +38.4 pp |
| FY2019 | -22.0% | -23.7 pp |
| FY2018 | 1.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating incomeBGLC Operating marginBGLC Operating cash flowBGLC Free cash flowBGLC Capital expendituresBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →